Observational studyCancer biology & therapy2019

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Teresa Gamucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.